Desjardins et al. published their phase I trial of 61 patients with recurrent GBM who received intratumoral infusions of PVSRIPO, a recombinant poliovirus that recognizes CD155, the poliovirus receptor which is highly expressed on GBM cells [210, 211]. This evidence concerns the gene PVR and glioblastoma.